Amylyx Pharmaceuticals, Inc. (AMLX): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$81.42M
Year ended 2024-12-31
$355.35M2022-12-31: $19.24M2023-12-31: $355.35M2024-12-31: $81.42M$81.42M
2022-12-31 Gross Profit (USD) 2024-12-31
Period endedGross ProfitChange YoYSource filing
2024-12-31$81.42M-77.1%2026-03-03, From 2024-01-01
2023-12-31$355.35Mn/m2025-03-04, From 2023-01-01
2022-12-31$19.24Mn/a2024-02-22, From 2022-01-01